NexImmune is a clinical-stage biotechnology company that develops treatments with curative potential for cancer and immune-mediated diseases using its proprietary Artificial Immune Modulation technology platform. The company has three product candidates, including NEXI-001, in Phase I/II clinical trials for acute myeloid leukemia, NEXI-002 in Phase I/II clinical trials for multiple myeloma, and NEXI-003 in the preclinical stage for the treatment of HPV-associated malignancies. NexImmune was founded in 2011 and is headquartered in Gaithersburg, Maryland.